Zealand Pharma reports positive phase III results against congenital hyperinsulinism

In a phase III study of dasiglucagon, biotech firm Zealand Pharma has met its endpoint, reducing the need for children under 12 months with the rare disorder to undergo intensive hospital treatment by 55%.

Photo: Zealand Pharma / PR

On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs